Management of Hyperbilirubinemia in Acute Cholangitis

Initial Assessment and Management

Acute cholangitis presents with varying severity, ranging from self-limiting to life-threatening disease, requiring tailored treatment approaches 1
Severity assessment should be performed using established criteria such as the Tokyo Guidelines, which classify cholangitis as Grade III (severe), Grade II (moderate), or Grade I (mild) 1, 2

Initiate empiric broad-spectrum antibiotics immediately upon suspicion of cholangitis, with administration within 1 hour for patients with septic shock and within 4 hours for others 2, 3
Recommended antibiotic regimens include 4th-generation cephalosporins, piperacillin/tazobactam, imipenem/cilastatin, meropenem, ertapenem, or aztreonam, with consideration of adding fluconazole in fragile patients or cases of delayed diagnosis 4, 5
Duration of antibiotic therapy is typically 3-5 days with successful biliary drainage, but may be continued until anatomical resolution in cases of residual stones or ongoing obstruction 2

Endoscopic retrograde cholangiopancreatography (ERCP) with biliary drainage is the first-line procedure for managing hyperbilirubinemia in acute cholangitis, with urgent decompression for severe cases and early decompression within 24 hours for moderate cases 3, 6
Endoscopic options include nasobiliary drain placement and endoscopic sphincterotomy with stone extraction 2, 3

Percutaneous transhepatic biliary drainage (PTBD) should be reserved for patients in whom ERCP fails or is not feasible, due to higher risks of complications 3
Open surgical drainage should only be used when endoscopic or percutaneous approaches are contraindicated or unsuccessful 3

Obtain bile samples for microbial testing at the beginning of drainage procedures and monitor bilirubin levels to assess response to treatment 2, 7
Consider long-term prophylactic antibiotics and evaluate for liver transplantation in patients with recurrent cholangitis 7

Initial management of dominant strictures from primary sclerosing cholangitis (PSC) with hyperbilirubinemia should include endoscopic dilatation with or without stenting, and brush cytology and/or endoscopic biopsy should be performed to exclude malignancy prior to endoscopic therapy 7

Delaying antibiotic administration in severe cases can lead to increased mortality, and failure to obtain adequate biliary drainage is associated with poor outcomes 2, 4
Overlooking the possibility of fungal infection in patients not responding to antibiotic therapy and underestimating the need for ICU admission in patients with severe cholangitis can also lead to adverse outcomes 8, 2